...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
Message: Snippet on Alexion / Soliris

Found this in a Forbes article... claims that only 1/3 of Soliris sales are US. So EMA registration just as good if not better than FDA? As I mentioned in a previous post... I believe RVX has been having good traction with KOLs in Europe. And remember that a Renal/CKD trial is being embedded in BOM.

"Soliris treats two diseases, one in which the body destroys its own blood cells, and another where it eats away at the kidneys. Most medicines get the bulk of their sales in the U.S., because drug prices here are higher. But only 1/3 of Soliris patients are in the U.S. The rest are split evenly between Europe, where most countries have single-payer systems that are fussy about drug prices, and, even more amazingly, the rest of the world, where there are price controls."

Share
New Message
Please login to post a reply